Suppr超能文献

心包积液:剑突下心包造口术与经皮导管引流术的比较

Pericardial effusion: subxiphoid pericardiostomy versus percutaneous catheter drainage.

作者信息

Allen K B, Faber L P, Warren W H, Shaar C J

机构信息

Department of Cardiovascular and Thoracic Surgery, Rush-Presbyterian-St. Lukes Medical Center, Chicago, Illinois, USA.

出版信息

Ann Thorac Surg. 1999 Feb;67(2):437-40. doi: 10.1016/s0003-4975(98)01192-8.

Abstract

BACKGROUND

Optimal management of cardiac tamponade resulting from pericardial effusion remains controversial.

METHODS

Cardiac tamponade in 117 patients was treated with either subxiphoid pericardiostomy (n = 94) or percutaneous catheter drainage (n = 23). Percutaneous catheter drainage was used for patients with hemodynamic instability that precluded subxiphoid pericardiostomy. Effusions were malignant in 75 (64%) of 117 patients and benign in 42 (36%) of 117.

RESULTS

Subxiphoid pericardiostomy had no operative deaths and a complication rate of 1.1% (1 of 94). In contrast, percutaneous drainage had significantly (p < 0.05) higher mortality and complication rates of 4% (1 of 23) and 17% (4 of 23), respectively. Patients with an underlying malignancy had a median survival of 2.2 months, with a 1-year actuarial survival rate of 13.8%. In comparison, patients with benign disease had a median survival of 42.8 months and a 1-, 2-, and 4-year actuarial survival rate of 79%, 73%, and 49%, respectively (p < 0.05). Effusions recurred in 1 (1.1%) of 94 patients after subxiphoid pericardiostomy compared with 7 (30.4%) of 23 patients with percutaneous drainage (p < 0.0001).

CONCLUSIONS

Benign and malignant pericardial tamponade can be safely and effectively managed with subxiphoid pericardiostomy. Percutaneous catheter drainage should be reserved for patients with hemodynamic instability.

摘要

背景

因心包积液导致的心包填塞的最佳治疗方法仍存在争议。

方法

117例心包填塞患者接受了剑突下心包造口术(n = 94)或经皮导管引流术(n = 23)治疗。经皮导管引流术用于血流动力学不稳定、无法进行剑突下心包造口术的患者。117例患者中75例(64%)的积液为恶性,42例(36%)为良性。

结果

剑突下心包造口术无手术死亡病例,并发症发生率为1.1%(94例中的1例)。相比之下,经皮引流的死亡率和并发症发生率显著更高(p < 0.05),分别为4%(23例中的1例)和17%(23例中的4例)。患有潜在恶性肿瘤的患者中位生存期为2.2个月,1年精算生存率为13.8%。相比之下,患有良性疾病患者的中位生存期为42.8个月,1年、2年和4年精算生存率分别为79%、73%和49%(p < 0.05)。剑突下心包造口术后94例患者中有1例(1.1%)积液复发,而经皮引流的23例患者中有7例(30.4%)复发(p < 0.0001)。

结论

剑突下心包造口术可安全有效地治疗良性和恶性心包填塞。经皮导管引流术应仅用于血流动力学不稳定的患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验